CLARUS BIOTECH REVIEW · LISTENING LIBRARY
Make room for a different perspective.
Build your own article podcast, or explore a complete four-pillar listening set.
Your personal podcast is a listening queue made from existing article recordings. It is saved only in this browser, without account syncing or a new audio-generation charge. It is not a podcast-app RSS subscription. Recordings are checked again when you press Play; a removed or changed recording may be unavailable.
My podcast
Loading your browser’s queue…
Four perspectives
The founding collection: four perspectives
One article from each pillar, using the recorded voices listed below.
- Liver-chip validation: the evidence and investment gate for a NAM · Bella
- Liposomal delivery: when usable yield changes the investment case · Bella
- Inclisiran access: the referral queue behind an infrequent injection · Hermione
- The cancer-vaccine option: finance the evidence before counting the payment · Hermione
Podcast archive
No monthly listening sets have been archived yet. The founding collection is available above.
Build your own podcast
74 article recordings listed.
- The cancer-vaccine option: finance the evidence before counting the payment
Hermione · 12 min
- Inclisiran access: the referral queue behind an infrequent injection
Hermione · 15 min
- Liposomal delivery: when usable yield changes the investment case
Bella · 17 min
- Liver-chip validation: the evidence and investment gate for a NAM
Bella · 17 min
- When the Clinical Trial Comes Home
Hermione · 6 min
- Could Your Digital Twin Help Choose a Treatment?
Hermione · 6 min
- The Invisible Factory Behind Every Breakthrough
Hermione · 7 min
- One Treatment, a Lifetime of Questions
Hermione · 7 min
- Who Will Invent the Next Medicine—Scientists, AI, or Both?
Hermione · 7 min
- What Does Getting Better Actually Feel Like?
Hermione · 6 min
- A Human Organ Small Enough for a Chip
Hermione · 6 min
- The Medicine We Hope Not to Need
Hermione · 6 min
- The Medicines We Never Get: Why Promising Science Fails to Reach Patients
Hermione · 9 min
- The Patient in 2035: What Could a Day of Healthcare Look Like?
Hermione · 8 min
- Clinical authorization and freedom to operate are separate milestones
Hermione · 7 min
- From Alpine to the next readout: define what the acquisition price did not resolve
Hermione · 7 min
- Buying an oncology platform does not buy a completed integration
Hermione · 6 min
- The $22 billion headline is not the cash available to develop an ADC
Hermione · 7 min
- A royalty can finance the next mission—or be sold to fund it sooner
Hermione · 7 min
- Entresto’s lifecycle asks a harder question: where should the field team go next?
Hermione · 7 min
- What cardiovascular evidence adds to an access dossier
Hermione · 7 min
- A price cut needs a volume hurdle and an access diagnosis
Hermione · 6 min
- After Humira: build a price–volume bridge, not a patent-cliff slogan
Hermione · 7 min
- A valuable cure can still create a treatment queue
Hermione · 7 min
- A device investment committee needs the sham-control question
Hermione · 6 min
- What is a second manufacturing source actually worth?
Hermione · 7 min
- Data integrity is an acquisition workstream with its own clock
Hermione · 7 min
- The CAR-T slot is a promise across two organizations
Hermione · 7 min
- Casgevy’s delivery lesson: patient benefit still needs a treatment slot
Hermione · 7 min
- A safety action can reset the addressable population overnight
Hermione · 7 min
- External controls in neurology: price the uncertainty before the next raise
Hermione · 7 min
- When a Phase II response is not a filing strategy
Hermione · 7 min
- From HER2 to ESR1: the diagnostic can set the launch clock
Hermione · 7 min
- Imatinib’s targeting lesson: fund the evidence bridge before the pivotal leap
Hermione · 7 min
- Measure an advisory engagement by the decision it improves
Hermione · 8 min
- From evidence to execution: an operating model for lean biotech teams
Hermione · 9 min
- The biotech value curve: define what changes at each evidence gate
Hermione · 9 min
- Biotech partnering: qualify the decision before building the contact list
Hermione · 8 min
- AI biotech financing: measure the evidence purchased by a larger round
Hermione · 8 min
- The founder translation gap: turn a scientific signal into a decision brief
Hermione · 9 min
- Vascular therapeutics: protect the outcome while improving the treatment burden
Hermione · 9 min
- Metabolic disease: sequence indications around evidence, capacity and access
Hermione · 9 min
- Rare disease: the comparator, the patient pathway and the capital milestone
Hermione · 10 min
- Oncology value inflection: matching evidence, capital and the treatment setting
Hermione · 10 min
- Women’s health: translating trial response into accessible, durable value
Hermione · 9 min
- AI value inflection: from technical promise to measurable enterprise value
Hermione · 9 min
- Read the deal structure: upfront value and contingent milestones are different
Hermione · 6 min
- Capital readiness: connect runway to the next credible evidence package
Hermione · 6 min
- Engineer the Phase II decision: milestones should retire a defined uncertainty
Hermione · 6 min
- Drug-development economics: make the assumptions visible
Hermione · 7 min
- Supply resilience is part of access: reading drug-shortage statistics carefully
Hermione · 6 min
- Biosimilar access: approval creates an option, implementation creates reach
Hermione · 6 min
- Microneedle vaccine patches: bridge immunogenicity to real-world usability
Hermione · 7 min
- Antibody–drug conjugates: delivery performance includes the safety burden
Hermione · 7 min
- RNA delivery and endpoint discipline: lessons from the ORION trials
Hermione · 7 min
- Selection biomarkers: an evidence design decision, not a success guarantee
Hermione · 6 min
- Accelerated approval: build the confirmation plan into the value story
Hermione · 6 min
- Beyond the approval count: what an innovation landscape can tell us
Hermione · 6 min
- MiniMed 670G: a closed-loop claim needs one system evidence map
Hermione · 4 min
- CureVac’s CVnCoV: platform promise needs candidate-level stop rules
Hermione · 5 min
- Amgen v. Sanofi: antibody breadth needs enabling evidence
Hermione · 4 min
- Provenge: survival benefit did not remove commercial constraints
Hermione · 5 min
- qHTS: automate the evidence, then measure the workflow
Hermione · 5 min
- Cold-chain evidence: the Pfizer vaccine illustrates a stability milestone
Hermione · 5 min
- Annovera: a reusable format still needs efficacy and usability evidence
Hermione · 4 min
- TGN1412: medical ownership must precede first exposure
Hermione · 5 min
- Patisiran: connect RNA interference to a neuropathy endpoint
Hermione · 5 min
- Cologuard: test sensitivity is the start of a screening pathway
Hermione · 5 min
- Exubera: field scale cannot repair an unaccepted proposition
Hermione · 5 min
- Aduhelm: an approval date was not an access-ready launch
Hermione · 4 min
- Ivacaftor: engineer a milestone around a defined mutation
Bella · 5 min
- Sickle-cell gene therapy: access is an agreement and a care pathway
Hermione · 4 min
- Afrezza: inhaled delivery brings a pulmonary workflow
Hermione · 4 min
- Remdesivir and ACTT-1: five fewer recovery days is a specific claim
Hermione · 5 min